Global Cancer Pain Market - 2024-2031

Global Cancer Pain Market - 2024-2031

The global cancer pain market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

The global cancer pain market designed for the pharmaceutical and medical devices sector focused on addressing pain associated with cancer. Cancer pain can arise from various factors, including the tumor pressing on nerves or organs, treatments like chemotherapy or radiation, or cancer-related procedures, Managing cancer pain is crucial for improving patients' quality of life and overall well-being.

The cancer pain market is often related to different oncology disorders and is one of the major complications of cancer disorder. The nature of cancer pain primarily depends on the type of cancer, stage, and intervention such as targeted therapy and chemotherapy used in the treatment of cancer. The cancer pain initiates because of the enlargement of the tumor mass reducing bones, nerves, and other organs.

Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostics procedures, or the skin, nerve, and the other changes caused by a hormone imbalance or immune responses. Cancer pain may originate from the actual disease state or related treatments including chemotherapy, surgery, and other medicines. This pipeline of innovative treatments is helping to meet the rising demand.

Market Dynamics: Drivers

The growing cancer prevalence

The global cancer pain market is driven by multiple factors. The growing number of cancer cases globally, with millions of new cases reported annually, is the key factor propelling market growth.

The global cancer pain market is a vital sector in the healthcare industry that has managed to support and diminish pain in individuals with cancer. It encloses various pharmaceutical and non-pharmaceuticals providing personalized medication for cancer patients, including analgesic treatment, home health care services, and supportive therapies.

In addition, lifestyle modifications, and an aging population are driving growth in the industry. Cancer is a leading cause of death worldwide. In 2023, cancer claimed a total of 9.6 to 10 million people globally. This translates to over 26,300 cancer-related deaths every day.

This increase in cancer cases would drive the demand for effective pain management solutions, thereby fueling the cancer pain market growth. According to the National Center for Health Statistics, in 2023, approximately 1,958,310 new cases and 609,820 cancer deaths are projected to occur in the U.S.

Relief from physical, psychosocial, and spiritual problems through palliative care is possible for more than 90% of patients with advanced stages of cancer. Improved access to oral morphine is strongly recommended for the treatment of moderate to severe cancer pain, suffered by over 80% of people with cancer in the terminal phase.

Moreover, key player strategies such as partnerships and collaborations would drive the market. For instance, in 2023, Pfizer and Seagen collaborated to reinvent cancer treatment in the future. Pfizer's determination to tackle the problems associated with cancer and enhance healthcare outcomes was demonstrated by this partnership, which aims to create cutting-edge medications and vaccines that benefit patients worldwide.

Also, in 2023, to enhance its oncology pipeline with modern cancer therapies like pelabresib and tulminetostat, Novartis partnered with Morohosys AG. This purchase demonstrates Novarti's dedication to creating cutting-edge cancer treatment solutions and is in line with the company's strategy focus on oncology.

Restraints

Factors such as various side effects associated with pain medications, opioid misuse & addiction, high cost of the treatment, Lack of knowledge regarding pain assessment and management among clinicians, Unequal healthcare infrastructure and inflated healthcare expenses, stringent regulatory requirements for drug approvals, limited accessibility of cancer care management, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global cancer pain market is segmented based on drug class, application, route of administration, end-user, and region.

The opioids segment accounted for approximately 54.4% of the global cancer pain market share

The opioids segment is expected to hold the largest market share over the forecast period. The opioid segment of the global cancer pain market offers a wide variety of medications catering to different pain levels and patient needs. For example, codeine or tramadol were used to treat mild to moderate cancer pain, and stronger opioids like morphine, oxycodone, or fentanyl were frequently needed to treat severe pain. By attaching to opioid receptors in the brain and spinal cord, these opioids modify how pain is perceived.

In 2023, an NCBI study released, that moderate-to-severe pain is experienced by about 30.6% of cancer patients throughout their illness, and 44.5% of patients suffer pain overall. This indicates that cancer pain is a considerable burden for patients. Opioids are essential for controlling cancer pain, offering efficient relief, and enhancing the quality of life for patients.

In addition, industry major players launch innovative products helps to drive the market. For instance, in October 2022, Parker Laboratories Inc. will expand its analgesic line, introducing Helix CBD Therapy Cream, CBD Clinical Cream, and Tri-Active Cream to its HelixTM brand, complementing its existing range of pain relief creams and medical contact media.

Also in July 2021, Venus Remedies Limited announced the launch of a consumer healthcare division that will provide various products for cancer pain management

Geographical Analysis

North America accounted for approximately 43.2% of the global cancer pain market share

North America region is expected to hold the largest market share over the forecast period. The region's cancer pain market is driven by several factors, including the increasing incidence of cancer cases, technological developments in the healthcare sector, the accessibility of pain management medicines, and the availability of a variety of chemotherapy treatment options.

In addition, the market is characterized by precision oncology and customized medicine, with increasing investments in genomics research & targeted therapy, and favorable healthcare infrastructure. Moreover, government initiatives such as Precision Medicine and Affordable Care Act, and well-organized reimbursement policies in this region support the market growth.

Moreover, 2 million Americans will receive a cancer diagnosis in 2024. An estimated 2,970 males and 310,720 women have experienced breast cancer. The second most common cancer diagnosis in Americans is prostate cancer. There were 2,99,010 recorded anticipated cases. The third most common cancer diagnosis is lung and bronchus cancer, with an estimated 2,34,580 new cases reported.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global cancer pain market. Those receiving cancer pain treatment during the COVID-19 epidemic had to acclimatize to several changes, including treatment plan modifications, delays, and disruptions, the absence of loved ones during in-person sessions, and altered provider communication as many appointments switched to telehealth. revealed that many patients had delays and disturbances in their care during the epidemic, which is consistent with earlier studies.

Even though most patients were aware of the necessity for additional safety measures, interruptions and delays made them feel more anxious and stressed.



During this time, the doctors need to be mindful of how nervous their patients are how overwhelmed they are, and how depressed they might be getting. Because on so many levels, it is just a recipe for becoming depressed, being sick with a terrible disease and being afraid of this COVID and being alone and isolated.”

Market Segmentation

By Drug Class
• Opioids
• NSAIDs
• Morphine
• Non-Opioids
• Nerve Blockers
• Others

By Application
• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Others

By Route of Administration
• Oral
• Parenteral
• Others

By End-Users
• Hospitals
• Homecare
• Specialty Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include CK Life Sciences (WEX Pharmaceuticals Inc), Mundipharma International., Orexo AB, DAIICHI SANKYO COMPANY, LIMITED., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., Grünenthal, Galena Biopharma, Meda Pharmaceuticals among others.

Key Developments

 On February 13, 2024, Radformation, a main supplier of radiation oncology software solutions, declared its strategic partnership with Icon Group. This collaboration unites the aptitude of the two organizations to change disease care through imaginative work processes and high-level software solutions.

 On January 25, 2024, Quibim, an organization working on changing imaging data into significant actionable data for cancer growth and treatment responses, collaborated with Merck KGaA. The collaboration means fostering high-level imaging-based diagnostics for accurate medication.



Why Purchase the Report??
• To visualize the global cancer pain market segmentation based on drug class, application, route of administration, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global cancer pain market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global cancer pain market report would provide approximately 70 tables, 71 figures, and 180 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies